Minerva Neurosciences, Inc. (NASDAQ: NERV) announced positive top line results from a Phase Ib clinical trial in major depressive disorder ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE